10x Genomics, Inc. (TXG)
| Market Cap | 8.56B +409.5% |
| Revenue (ttm) | 618.58M -3.6% |
| Net Income | -67.08M |
| EPS | -0.52 |
| Shares Out | 131.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,773,069 |
| Open | 60.46 |
| Previous Close | 59.28 |
| Day's Range | 59.41 - 66.47 |
| 52-Week Range | 15.12 - 102.81 |
| Beta | 2.03 |
| Analysts | Buy |
| Price Target | 68.14 (+4.75%) |
| Earnings Date | Nov 5, 2026 |
About TXG
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for TXG stock is "Buy." The 12-month stock price target is $68.14, which is an increase of 4.75% from the latest price.
News
10x Genomics price target lowered to $65 from $70 at JPMorgan
JPMorgan lowered the firm’s price target on 10x Genomics (TXG) to $65 from $70 and keeps a Neutral rating on the shares.
10x Genomics price target lowered to $65 from $80 at BofA
BofA lowered the firm’s price target on 10x Genomics (TXG) to $65 from $80 and keeps a Neutral rating on the shares. The firm says the company’s showed progress ahead…
10x Genomics price target lowered to $61 from $90 at UBS
UBS analyst Doug Schenkel lowered the firm’s price target on 10x Genomics (TXG) to $61 from $90 and keeps a Neutral rating on the shares.
10x Genomics price target lowered to $55 from $70 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $55 from $70 and keeps a Hold rating on the shares.The firm updated its model…
10x Genomics price target lowered to $61 from $90 at UBS
UBS lowered the firm’s price target on 10x Genomics (TXG) to $61 from $90 and keeps a Neutral rating on the shares. 10x Genomics delivered largely in-line results with upside…
10x Genomics price target raised to $68 from $50 at Stifel
Stifel raised the firm’s price target on 10x Genomics (TXG) to $68 from $50 and keeps a Buy rating on the shares.
10x Genomics price target raised to $60 from $50 at Citi
Citi raised the firm’s price target on 10x Genomics (TXG) to $60 from $50 and keeps a Neutral rating on the shares.
10x Genomics price target lowered to $70 from $110 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $70 from $110 and keeps an Overweight rating on the shares. The firm updated the company’s…
10x Genomics reports Q3 EPS (15c) vs. (22c) last year
Reports Q3 revenue $150.7M, consensus $147.85M. Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026. “The biggest highlight of the quarter was the start…
10x Genomics raises 2026 revenue view to $625M-$635M from $610M-$630M
2026 revenue consensus $620.58M.
10x Genomics Earnings Call Transcript: Q3 2026
Q3 revenue rose 1% YoY, with consumables growth and 16% spatial consumables growth. Strong Atera demand drove higher FY26 guidance, while manufacturing and installation capacity constrain the ramp and weigh on near-term margins.
10x Genomics Earnings release: Q3 2026
10x Genomics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
10x Genomics Prepared remarks: Q3 2026
10x Genomics filed a regulatory document on November 5, 2026 disclosing important business information.
10x Genomics Quarterly report: Q3 2026
10x Genomics has published its Q3 2026 quarterly earnings report on November 5, 2026.
10x Genomics Reports Third Quarter 2026 Financial Results
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financi...
10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
Powered by Anthropic's Claude, Sentira Single Cell enables researchers to analyze Chromium data using natural language, accelerating the path from scientific questions to experimental conclusions PLEA...
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that ...
10x Genomics downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded 10x Genomics (TXG) to Equal Weight from Overweight with an unchanged price target of $65.
Stephens downgrades Illumina and 10x Genomics following outperformance
As previously reported, Stephens analyst Mason Carrico downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213, and 10x Genomics (TXG) to Equal…
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will rep...
10x Genomics price target raised to $70 from $47 at TD Cowen
TD Cowen raised the firm’s price target on 10x Genomics (TXG) to $70 from $47 and keeps a Hold rating on the shares. The firm updated its model as they…
10x Genomics price target raised to $70 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on 10x Genomics (TXG) to $70 from $40 and keeps an Equal Weight rating on the shares.
10x Genomics price target raised to $100 from $60 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $100 from $60 and keeps a Buy rating on the shares. The firm sees increasing utilization…
10x Genomics price target raised to $80 from $50 at BofA
BofA raised the firm’s price target on 10x Genomics (TXG) to $80 from $50 and keeps a Neutral rating on the shares. The life science tools sector has further re-rated…
10x Genomics announces research collaboration with Fred Hutchinson
10x Genomics (TXG) announced a multi-project research collaboration with Fred Hutchinson Cancer Center, one of the nation’s leading cancer research institutions, to advance the use of single cell and ...